Navigation Links
ActivBiotics Outlines a Clinical Path Forward to Examine if Rifalazil Is Superior to Azithromycin in the Treatment of Chlamydia STD
Date:2/19/2008

WELLESLEY HILLS, Mass., Feb. 19 /PRNewswire/ -- Joseph F. Finn, Jr., CPA, the Assignee for the Benefit of Creditors of ActivBiotics, announced today the design of a clinical trial to investigate whether Chlamydia STD is treated adequately by currently approved antibiotics. Rifalazil, the most potent anti-chlamydial agent that has been administered to people, may provide a better treatment option for Chlamydia STD. The insidious aspect of Chlamydia STD is that infections which are inadequately treated can later result in serious consequences. A new, improved treatment would prevent the long-term detrimental effects of Chlamydia STD, which for women include mucopurulent cervicitis, pelvic inflammatory disease, ectopic pregnancy, and infertility. Chlamydia STD infections have also been associated with increased transmission of human immunodeficiency virus (HIV) in both men and women.

At the present time, the prevailing medical opinion is that Chlamydia STD is treated adequately by a single 1 gram oral dose of azithromycin. However, in a previous Phase II clinical trial (published in 2007 in the journal Sexually Transmitted Diseases), men experiencing symptoms of nongonococcal urethritis attributed to Chlamydia trachomatis infection had higher cure rates with rifalazil than with azithromycin five weeks after treatment. Although the sample size of the trial was small, these results certainly left room to consider the possibility of an improved therapy with rifalazil for treating all Chlamydia STDs.

The new trial would compare a group of women, all infected with Chlamydia STD, who would be administered a single oral dose of rifalazil with a similar group receiving a single dose of azithromycin. "We can examine if rifalazil is superior to azithromycin in eradicating Chlamydia STD in women by evaluating 55 subjects in each treatment group", said Walter Stamm from the University of Washington, a leading clinician in the area of Chlamydia STD. Indeed, such a result would be welcome news to the million women in the US infected with Chlamydia STD according the Centers for Disease Control and Prevention.

The sale of ActivBiotics' assets, including rifalazil, is being conducted through an Assignment for the Benefit of Creditors. The bidding for the assets, which may be purchased separately or in combination, is scheduled for March 14, 2008.

For additional information on the terms of sale and to obtain a bidder's package, please contact Joseph F. Finn, Jr., CPA (jffinnjr@earthlink.net, phone 781-237-8840), Finn, Warnke & Gayton, 167 Worcester Street, Suite 201, Wellesley Hills, MA 02481-3613. For technical information on the assets, please contact Christo Shalish, cshalish@activbiotics.com.


'/>"/>
SOURCE ActivBiotics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. ActivBiotics Receives Orphan Drug Designation from the European Medicines Agency for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis Indication
2. ActivBiotics to Present Results of Pivotal Study in the Treatment of Peripheral Arterial Disease at AHA Meeting
3. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
4. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
5. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
6. First Clinical Volumetric Modulated Arc Therapy Treatment Completed With Elekta Synergy(R) S at General Hospital Vienna
7. Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented at the American Society for Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium
8. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
9. Maine Natural Health Company Conducts Dental Clinical Trial
10. Clinical Update - Decapeptyl(R)/Trelstar(R) 6-Month Formulation in Advanced Prostate Cancer
11. AGI Dermatics Clinical Data Indicate Bicyclic Monoterpene Diols Suppress MMP1 and Stimulate Collagen Through TNF-a Signaling
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the addition ... States, China, Japan, Brazil, United Kingdom, Germany, France, Italy, ... Surgical Procedure Volumes: Global ... surgical procedure volume data in a geographic context. The ... of growth drivers and inhibitors, including world population growth, ...
(Date:6/23/2016)... -- The Biotechnology industry might still be ... opportunities to investors. Stock-Callers.com assesses the recent performances of ... XON ), Vertex Pharmaceuticals Inc. (NASDAQ: ... ), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ... complimentary trade alerts at: http://stock-callers.com/registration ...
(Date:6/23/2016)... , June 23, 2016 Leading BioSciences ... address medical conditions resulting from a breakdown of ... appointed Greg Doyle as chief executive ... BioSciences, executive management team and board of directors, ... financial officer. He will provide continued leadership and ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ... , "Film editors can give their videos a whole new perspective by using the ... CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets ...
(Date:6/26/2016)... ... , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a ... fitness app plans to fix the two major problems leading the fitness industry today:, ... type program , They don’t eliminate all the reasons people quit their exercise ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts ... applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention ... health care topics including advance care planning, healthcare costs and patient and family ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
Breaking Medicine News(10 mins):